An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice

Roche

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Drug: Tocilizumab

Study type: Observational

Funder types: Industry; Other

Identifiers

NCT02552940

ML29691

Details and patient eligibility

About

This observational trial will evaluate the effectiveness, the consistency of evaluation scores, quality of life, safety and tolerability of TCZ administered subcutaneously (SC) in participants with RA in daily clinical practice.

Enrollment: 140 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants naive to TCZ or who have received TCZ SC treatment within 8 weeks prior to the enrolment visit can be included
• Participants in whom the treating physician has made the decision to commence TCZ SC in accordance with the label and reimbursement criteria

Exclusion criteria

• Participants who have received TCZ >8 weeks prior to the enrolment visit
• Participants who have previously received TCZ SC
• Participants who have received treatment with any investigational agent within 4 weeks before starting treatment with TCZ SC

Trial design

140 participants in 1 patient group

Rheumatoid Arthritis participants treated with Tocilizumab SC

Description:

Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.

Treatment:

Drug: Tocilizumab